MYOV News and Press, Myovant Sciences Ltd. From 05/11/22

Image source: The Motley Fool. Myovant Sciences Ltd. (NYSE: MYOV) Q4 2021 Earnings Call May 10, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Myovant Sciences Ltd. (MYOV) Q4 2021 Earnings Call Transcript

Myovant Sciences Ltd. (MYOV) Q4 2021 Earnings Conference Call May 10, 2022 08:30 AM ET Company Participants Uneek Mehra - Chief Financial & Business Officer Dave Marek - Chief Executive Officer Lauren Merendino - Chief Commercial Officer Juan Camilo Arjona - Chief Medical Officer Conferen...

Myovant Sciences (NYSE:MYOV) stock rose ~25% on May 10 after the company's Q4 results. Q4 total revenues grew ~134% Y/Y to $57.57M, but missed analysts' estimates. Pfizer collaboration revenue amounted to $25.14M, compared to ~$20.98M in Q4 2021. Myovant is expecting FDA decision by Aug. 6&#x...

U.S. Food and Drug Administration (FDA) approval received for VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for treatment of H. pylori infection in adults Up to $260 million revenue...

Myovant Sciences press release (NYSE:MYOV): Q4 GAAP EPS of -$0.63 misses by $0.09. Revenue of $57.6M (+134.1% Y/Y) misses by $14.74M. Shares -1.03% PM. For further details see: Myovant Sciences GAAP EPS of -$0.63 misses by $0.09, revenue of $57.6M misses by $14.74M

Fiscal year 2021 total revenue of $231.0 million, including net product revenues of $94.3 million; fourth fiscal quarter 2021 total revenues of $57.6 million, including net product revenue of $32.4 million European Commission approval of ORGOVYX ® as the first a...

Myovant Sciences (NYSE:MYOV) FQ4 consensus EPS estimate is -$0.52 and consensus revenue estimate is $72.34M. MYOV is scheduled to announce FQ4 earnings results tomorrow, May 10, before market open. Over the last 3 months, EPS and revenue estimates have seen 0 upward revision&#x...

Commercial-stage biotech, Myovant Sciences (NYSE:MYOV) has partnered with U.K.-based pharmaceutical company Accord Healthcare to introduce prostate cancer therapy, Orgovyx in Europe. The exclusive license agreement covers the European Economic Area, United Kingdom, Switzerland, and Turkey. Pe...

Myovant to receive an upfront payment of $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to $90.5 million Myovant also eligible to receive tiered royalties from the high-teens to mid-twenties on net sales BASE...

Vinco Ventures (BBIG) +33% on confirming distribution date for planned spin-off of blockchain business Cryptyde. Funko (FNKO) +20% after attracting new investor, striking deal with eBay. Opendoor Technologies (OPEN) +14% on Q1 results. ChemoCentryx (CCXI) +1...